Capacity is product- and stage-specific
A site that can make one bulk antigen may not have the process, containment, formulation, fill line, assays, approvals, or commercial rights for another. Technology platforms shorten some redesign steps while product-specific validation remains.
Three numbers that locate the frontier
WHO market counts and concentration reflect the products and reporting coverage in its dataset. Nominal facility capacity is not equivalent to released doses or equitable access.
Measure released doses delivered on time
Manufacturing yield compounds across upstream production, purification, formulation, fill-finish, testing, and distribution. A bottleneck at any one stage can idle the rest.
Long quality-control and regulatory lead times can make physical production faster than batch release.
Campaign scheduling and uncertain demand can make small markets unattractive despite large public-health value.
The headline metric sits on a system
Each layer can become the bottleneck even when the layer before it improves.
Platform and inputs
Cell banks, plasmids, enzymes, lipids, media, vials, stoppers, and single-use systems establish the recipe and supply base.
- Measure
- Qualified suppliers · lead time
- Failure mode
- Specialized inputs
Drug substance
Culture, synthesis, harvest, purification, and concentration create active material.
- Measure
- Yield · batch success
- Failure mode
- Biological variability
Drug product
Formulation, sterile filtration, filling, inspection, labeling, and packaging create doses.
- Measure
- Doses/hour · rejects
- Failure mode
- Aseptic capacity
Release and delivery
Potency, sterility, stability, regulation, procurement, cold chain, and administration complete supply.
- Measure
- Released doses on time
- Failure mode
- Testing and last mile
Sterility and potency require evidence for every process
Biological products cannot be defined only by a chemical formula. Process control and validated assays demonstrate identity, purity, potency, and safety, imposing time and sampling even when equipment is fast.
Emergency expansion moves into peacetime sustainability
New regional capacity survives only with products, procurement commitments, workforce, maintenance, quality maturity, and supply networks during ordinary years.
Platform facilities
Reuse equipment, analytics, and trained teams across related products.
Diversify critical inputs
Qualify suppliers before shortages force changes.
Strengthen release labs
Expand reference standards and testing capacity alongside reactors.
Shape demand
Use pooled procurement and advance commitments to support viable production.
An optimistic view, with conditions
Manufacturing resilience becomes a portfolio
Regions can build durable capability by pairing routine immunization demand with flexible platforms, interoperable regulation, trained workforces, and emergency options.
Sources, method, and boundaries
Market volume and concentration use WHO's published dataset. The stack distinguishes physical capacity, validated product capability, released supply, and administered access.
